Roth Capital Lowers Earnings Estimates for Niagen Bioscience

Key Points

• Roth Capital has lowered its earnings per share estimate for Niagen Bioscience for FY2026 from $0.13 to $0.12, maintaining a "Buy" rating with a $23.00 target price.
• The stock of Niagen Bioscience has seen a decline of 6.5%, opening at $7.38, with a market cap of $588.56 million.
• Institutional investors have increased their stake in the company, with Bank of America enhancing its position by 89.5% in the fourth quarter.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Roth Capital lowered their FY2026 earnings per share estimates for shares of Niagen Bioscience in a research report issued on Wednesday, October 1st. Roth Capital analyst S. Mcgowan now forecasts that the company will earn $0.12 per share for the year, down from their prior estimate of $0.13. Roth Capital currently has a "Buy" rating and a $23.00 target price on the stock.

A number of other research analysts have also recently issued reports on NAGE. Canaccord Genuity Group lifted their target price on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. HC Wainwright lifted their price objective on Niagen Bioscience from $11.00 to $12.00 and gave the company a "buy" rating in a research report on Monday, August 11th. Finally, Wall Street Zen lowered Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, September 9th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $13.42.

Niagen Bioscience Stock Down 6.5%

NASDAQ:NAGE opened at $7.38 on Friday. The firm has a market cap of $588.56 million, a PE ratio of 35.14 and a beta of 2.13. Niagen Bioscience has a 12 month low of $3.18 and a 12 month high of $14.69. The company's 50-day moving average price is $9.62 and its two-hundred day moving average price is $9.47.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The firm had revenue of $31.12 million for the quarter, compared to analysts' expectations of $28.55 million. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Hedge Funds Weigh In On Niagen Bioscience

Large investors have recently made changes to their positions in the company. Bank of America Corp DE increased its position in Niagen Bioscience by 89.5% in the fourth quarter. Bank of America Corp DE now owns 52,144 shares of the company's stock worth $277,000 after purchasing an additional 24,622 shares during the period. Two Sigma Investments LP bought a new stake in Niagen Bioscience in the fourth quarter valued at about $675,000. Finally, Millennium Management LLC acquired a new position in shares of Niagen Bioscience during the 4th quarter worth about $1,199,000. Institutional investors and hedge funds own 15.41% of the company's stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.